Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
Gilead Sciences reported that its experimental once-daily pill, emvistegrast, eliminated symptoms for patients and met its main goal in a mid-stage trial for ulcerative colitis. The oral treatment achieved stronger remission rates compared to a placebo and outpaced Entyvio in the mid-stage bowel disease study. These positive findings position the company to advance the asset into Phase 3 testing. The trial success strengthens the biotechnology firm's ongoing portfolio expansion into treatments for inflammatory and autoimmune conditions, drawing strong interest from industry analysts who view the candidate as a foundational asset.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Gilead Sciences stated on Monday that its experimental once-daily pill, emvistegrast, reduced symptoms of a chronic bowel illness in more patients than placebo in a mid-stage trial.
- ✓ The drug was tested in adults with moderate to severe ulcerative colitis.
- ✓ Gilead plans to advance the oral alpha-4 beta-7 inhibitor into Phase 3 testing.
What changed
Gilead Sciences announced that its experimental once-daily oral pill, emvistegrast, successfully met its main endpoint in a mid-stage ulcerative colitis trial.
Live updates
-
Gilead IBD Pill Eliminates Symptoms in Phase 2 Study
Gilead Sciences reported that its experimental once-daily pill, emvistegrast, eliminated symptoms for patients and met its main goal in a mid-stage trial for ulcerative colitis. The oral treatment achieved stronger remission rates compared to a placebo and outpaced Entyvio in the mid-stage bowel disease study. These positive findings position the company to advance the asset into Phase 3 testing. The trial success strengthens the biotechnology firm's ongoing portfolio expansion into treatments for inflammatory and autoimmune conditions, drawing strong interest from industry analysts who view the candidate as a foundational asset.
Why it matters
The mid-stage success marks an advance for Gilead Sciences as the company works to diversify its revenue beyond traditional therapeutic areas. Inflammatory bowel diseases like ulcerative colitis require long-term management, and oral treatment options are highly valued by patients compared to injectable biologics. Gilead now plans to transition the program into late-stage clinical development.
What is confirmed
- Gilead Sciences stated on Monday that its experimental once-daily pill, emvistegrast, reduced symptoms of a chronic bowel illness in more patients than placebo in a mid-stage trial.
- The drug was tested in adults with moderate to severe ulcerative colitis.
- Gilead plans to advance the oral alpha-4 beta-7 inhibitor into Phase 3 testing.
Still unconfirmed
- Industry observers describe the experimental treatment as a foundational asset for the biotechnology firm following the phase 2 win.
What to watch next
- Initiation and design details of the upcoming Phase 3 clinical trial.
- Detailed efficacy and safety data presentations at upcoming medical meetings.
confidence 95%Sources used for this update (8)
- STAT — Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
- Fierce Biotech — Gilead ‘sitting on a foundational asset’ after oral UC drug's phase 2 win
- Endpoints News — Gilead’s pill posts stronger remission rates than Entyvio in ulcerative colitis
- Reuters — Gilead's pill succeeds in mid-stage bowel disease trial
- AllSci — Gilead's oral α4β7 inhibitor meets Phase II ulcerative colitis endpoint, Phase III planned
- www.statnews.com — Gilead's IBS drug succeeds in mid-stage trial | STAT
- kelo.com — Gilead’s pill succeeds in mid-stage bowel disease trial
- www.yahoo.com — Gilead's pill succeeds in mid-stage bowel disease trial - Yahoo
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community